BAO PHARMA-B(02659.HK) closed 9.16% higher, closing at HKD 27.4

NewTimeSpace · 2026/05/08 19:48 · By Xuran Lin

Tags：

BAO PHARMA-B 02659.HK

Related Topics

BAO PHARMA-B(02659.HK): Subcutaneous Infusion Ceftriaxone Sodium BJ007 FDA IND Approval
Shanghai Bao Pharmaceuticals(02659.HK): IND Application for Injection BJ044 Approved by NMPA

Finance
JIANGSU NEW VISION AUTOMOTIVE ELECTRONICS (02632.HK): Expected First-Half Pretax Loss of Approximately RMB 402 Million to 422 Million
Finance
China Ruyi (00136.HK): Expected First-Half Net Profit of Approximately RMB 800 Million to 900 Million
Finance
SenseTime-W (00020.HK): Expected First-Half Profit of Approximately RMB 500 Million to 700 Million
Finance
CanSino Biologics (06185.HK): NDA for Td5cp, a Diphtheria-Tetanus-Pertussis Vaccine for Adolescents and Adults, Accepted for Review
Finance
160 Health International Limited (02656.HK): Expected Turnaround to Profit in First Half, Net Profit of Approximately RMB 1 Million to 3 Million
Research
HK shares Newly Listed Stocks Tracking Weekly Report: No Lock-up Expiries Next Week; INNOGEN-B and HAIZHI TECH GP Both Down Over 13% for the Week - 20260814
Finance
CENTRAL CHINA MANAGEMENT COMPANY (09982.HK): Completion of Allotment and Issuance of 773 Million Subscription Shares
Finance
MemeStrategy, Inc. (02440.HK): Executive Director and Chief Investment Officer Li Minghong Resigns
Finance
Zhengye International (03363.HK): Expected First-Half Profit of No Less Than RMB 20 Million
Finance
RUICHANG INTERNATIONAL (01334.HK): Expected First-Half Loss Narrows to Approximately RMB 24.75 Million

Scan QR Code

Download App